GYRE
Price
$5.74
Change
-$0.12 (-2.05%)
Updated
Oct 23, 11:10 AM (EDT)
Capitalization
621.36M
14 days until earnings call
Intraday BUY SELL Signals
TRDA
Price
$4.52
Change
-$0.21 (-4.44%)
Updated
Oct 23, 11:16 AM (EDT)
Capitalization
184.17M
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GYRE vs TRDA

GYRE vs TRDA Comparison Chart in %
View a ticker or compare two or three
VS
GYRE vs. TRDA commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a Hold and TRDA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for GYRE with price predictions
Oct 22, 2026

GYRE in downward trend: 10-day moving average broke below 50-day moving average on October 15, 2026

The 10-day moving average for GYRE crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GYRE as a result. In 75 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.

The Moving Average Convergence Divergence Histogram (MACD) for GYRE turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 34 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

GYRE moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where GYRE advanced for three days, in 216 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

GYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 139 of 164 cases where GYRE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.757) is normal, around the industry mean (2.973). P/E Ratio (-29.300) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (6.536) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. GYRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
a Summary for TRDA with price predictions
Oct 22, 2026

TRDA's RSI Indicator climbs out of oversold territory

The RSI Indicator for TRDA moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 18 of the 20 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 63 cases where TRDA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.

Following a +14.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRDA advanced for three days, in 263 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

TRDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day moving average for TRDA crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 72%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for TRDA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.789) is normal, around the industry mean (2.973). P/E Ratio (-1.194) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (61.350) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. TRDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
GYRE: Fundamental Ratings
GYRE
OUTLOOK RATING
1..100
71
VALUATION
overvalued / fair valued / undervalued
1..100
7
Undervalued
PROFIT vs RISK RATING
1..100
95
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
76
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GYRETRDA
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
89%
Momentum
ODDS (%)
Bearish Trend 1 day ago
79%
N/A
MACD
ODDS (%)
Bearish Trend 1 day ago
83%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 10 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (GYRE: $5.86 vs. TRDA: $4.73)
Brand notoriety: GYRE and TRDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 48% vs. TRDA: 149%
Market capitalization -- GYRE: $621.36M vs. TRDA: $184.17M
GYRE [@Biotechnology] is valued at $621.36M. TRDA’s [@Biotechnology] market capitalization is $184.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 1 FA rating(s) are green while TRDA’s FA Score has 1 green FA rating(s).

  • GYRE’s FA Score: 1 green, 4 red.
  • TRDA’s FA Score: 1 green, 4 red.
According to our system of comparison, TRDA is a better buy in the long-term than GYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 5 TA indicator(s) are bullish while TRDA’s TA Score has 4 bullish TA indicator(s).

  • GYRE’s TA Score: 5 bullish, 5 bearish.
  • TRDA’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, TRDA is a better buy in the short-term than GYRE.

Price Growth

GYRE (@Biotechnology) experienced а -8.44% price change this week, while TRDA (@Biotechnology) price change was -1.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.05%. For the same industry, the average monthly price growth was -16.50%, and the average quarterly price growth was -16.80%.

Reported Earning Dates

GYRE is expected to report earnings on Nov 06, 2026.

TRDA is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (+1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
GYRE
Daily Signal:
Gain/Loss:
TRDA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with TRDA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
-0.68%
TRDA - GYRE
41%
Loosely correlated
+1.72%
NKTX - GYRE
39%
Loosely correlated
-0.57%
RCKT - GYRE
39%
Loosely correlated
+5.00%
CRSP - GYRE
39%
Loosely correlated
-1.01%
SPRC - GYRE
38%
Loosely correlated
-10.45%
More

TRDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRDA has been closely correlated with ENGN. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if TRDA jumps, then ENGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRDA
1D Price
Change %
TRDA100%
+1.72%
ENGN - TRDA
78%
Closely correlated
-3.07%
INSM - TRDA
44%
Loosely correlated
+1.08%
ARQT - TRDA
43%
Loosely correlated
+1.04%
PHAR - TRDA
42%
Loosely correlated
+12.55%
KRRO - TRDA
42%
Loosely correlated
+29.71%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VXX18.481.09
+6.27%
iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX)
DDDD34.270.65
+1.93%
YieldMax U.S. Stocks Target Double Distribution ETF
VIXM13.210.22
+1.69%
ProShares VIX Mid-Term Futures ETF (VIXM)
CGHY24.590.10
+0.41%
Capital Group High Yield Bond ETF
ARTY68.86-4.06
-5.57%
iShares Future AI & Tech ETF (ARTY)